Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis

doi:10.1001/jama.2020.26625

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In diabetic individuals with gastroparesis symptoms, metoclopramide nasal spray provides better symptom management than metoclopramide oral tablets. 107 , 108 Metoclopramide can pass the blood-brain barrier, which allows it to have more severe extrapyramidal adverse effects include tremors, sadness, anxiety, and, in rare instances, tardive dyskinesia. 109 , 110 Metoclopramide was given a black box warning by the FDA because of these risks in 2009.…”

Section: Treatment Of Diabetic Gastroparesismentioning

confidence: 99%

Common Pathophysiological Mechanisms and Treatment of Diabetic Gastroparesis

Zhang,

et al. 2024

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Diabetic gastroparesis (DGP) is a common complication of diabetes mellitus, marked by gastrointestinal motility disorder, a delayed gastric emptying present in the absence of mechanical obstruction. Clinical manifestations include postprandial fullness and epigastric discomfort, bloating, nausea, and vomiting. DGP may significantly affect the quality of life and productivity of patients. Research on the relationship between gastrointestinal dynamics and DGP has received much attention because of the increasing prevalence of DGP. Gastrointestinal motility disorders are closely related to a variety of factors including the absence and destruction of interstitial cells of Cajal, abnormalities in the neuro-endocrine system and hormone levels. Therefore, this study will review recent literature on the mechanisms of DGP and gastrointestinal motility disorders as well as the development of prokinetic treatment of gastrointestinal motility disorders in order to give future research directions and identify treatment strategies for DGP.

show abstract